Irish MedTech Company Medihive Receives €7 Million Investment
The business is now valued at €62 million following the investment. Medihive includes Ireland's largest online doctor service WebDoctor.ie. The investment will be used to fuel international growth, drive R&D innovation and accelerate healthcare software developments. Medihive will recruit up to 42 key hires across sales, engineering, doctors and marketing departments, adding to the 130 people already working with the company.
DUBLIN, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Medihive, Ireland's award-winning health technology platform, which includes Webdoctor.ie, has secured an investment from ResMed, an international leader in digital health and cloud-connected medical device innovation, as well as existing shareholders including VentureWave Capital. The investment now values the business at €62 million.
Medihive is a software company built to transform medical processes that don't work so patients can benefit from healthcare that does work. The business provides sophisticated software and clinical solutions to the healthcare, pharmacy and insurance industries, as well as direct to consumers and corporates via www.webdoctor.ie. The company combines digital and clinical know-how to bring clients and their end users high-quality virtual care on a global scale.
The €7 million investment announced today will be used to further increase the international growth of the business, drive investment and innovation in R&D and accelerate healthcare software developments. The company currently employs 130 people and it is expected this number will now increase by a further 42 employees over the next two years.
ResMed, whose cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases, enabling people to live healthier lives, has been working with Medihive since 2019 and now joins as an investor. ResMed Germany led deal negotiations on behalf of the organisation. As a result of their investment, ResMed will now take a seat on the board to work with the team to accelerate the growth of the business.
Meanwhile, existing shareholders in Medihive have invested additional capital into the business. This follows the €3 million investment in August 2021 by VentureWave Capital, the private equity firm that focuses on entrepreneurial companies that make a positive social impact, are in vital sectors and address UN Sustainable Development Goals. At the time of VentureWave Capital's €3 million in August 2021, the business was valued at €48 million. Today's investment now values the company at €62 million, a significant 29% increase.
Noel McSweeney, Chairman of Medihive, said: "The investment from ResMed alongside the increased support from current shareholders demonstrates our shared passion for medical technology advancement and will allow Medihive and Webdoctor.ie to further expand and develop our services while continuing to provide transformative digital healthcare solutions."
Katrin Pucknat, President of ResMed Germany, said:"At ResMed, our mission is to change 250 million lives in 2025 in out-of-hospital care settings, and today's announcement fits perfectly with that goal. Our work to date with Medihive has transformed the lives of our patients by making their care pathway less disjointed and allowing them to get diagnosed for sleep apnea outside of a hospital setting. ResMed places significant importance on innovation and this investment will enable both organisations to continue to be at the forefront of developments in healthcare technology. We look forward to supporting the team at Medihive as part of their board and believe this relationship will create new opportunities for us both while continuing to transform the healthcare industry."
David Crimmins, CEO of MediHive, said:"Medihive builds solutions to deliver positive patient outcomes by removing friction from their care journeys. This investment now comes at a pivotal moment for Medihive. Over the last two and a half years, demand for our services has surged as organisations realised they can achieve better patient outcomes by blending smart health technology with their traditional health infrastructures. This investment will enable us to continue meeting this demand while also allowing us to scale and expand our services in the continually evolving telehealth market both in Ireland and internationally. It's an exciting time for Medihive, and we're really looking forward to working with ResMed and our current shareholders to continue to make advances and improvements in digital healthcare for patients and professionals in the industry alike."
Alan Foy, Chairman and Managing Partner VentureWave Capital, said: "We are delighted to once again invest in Medihive alongside ResMed, a key strategic investor. As a successful Irish health technology business that's making an impact on delivering digital health and patient outcomes, this investment demonstrates our continued support and confidence in Medihive's business goals, global impact and strategic ambitions."
Inspiring a world where instant, frictionless access to healthcare is the norm.
Medihive, Welcome Tomorrow.
For more information, visit www.medihive.com
PR Senior Account Manager
To view this piece of content from cdn.newswire.com, please give your consent at the top of this page.
Image 1: David Crimmins CEO of MediHive and Katrin Pucknat President of ResMed Germany
To view this piece of content from cdn.newswire.com, please give your consent at the top of this page.
Image 2: Medihive
This content was issued through the press release distribution service at Newswire.com.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Storaktionærmeddelelse25.3.2023 14:30:37 CET | pressemeddelelse
Årets meddelelse nr. 20 Dato: 25. marts 2023 Storaktionærmeddelelse Det skal herved meddeles, at Pharma Equity Group A/S har modtaget meddelelse om at NK Invest ApS ejerandel, både direkte og indirekte via dennes ejerskab af Selskabet af 25. marts DK ApS og Selskabet af 25. marts II ApS, efter kapitalforhøjelse offentliggjort under selskabsmeddelelse nr. 16 af 24. marts 2023, udgør mindre end 5 % af den udstedte aktiekapital i Pharma Equity Group A/S. Alle henvendelser vedrørende ovenstående bedes venligst rettet til direktør Peter Ole Jensen på e-mail: email@example.com. Med venlig hilsen Pharma Equity Group A/S På bestyrelsens vegne
FCB Tops 2023 WARC Rankings for Creative Effectiveness24.3.2023 21:41:59 CET | Press release
FCB awarded #1 Creative Agency & #1 Campaign for Effectiveness in WARC Effective 100 NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) -- FCB was a top performer in the 2023 WARC Rankings, earning recognition as the #1 Creative Agency for Effectiveness in the WARC Effective 100, among other distinctions. Numerous FCB campaigns were honored as well, including Michelob ULTRA’s “Contract for Change,” which ranked as the #1 Campaign for Effectiveness. “Creative is the business and the business is creative. To separate the two does a disservice to the industry. We will continue to partner with our clients to create work that is both effective in the moment and impactful long term. FCB is honored that this Timely and Timeless approach to work is being recognized by WARC,” said Susan Credle, FCB Global Chair & Global CCO. In the Effective 100, FCB New York was named the #1 Creative Agency for Effectiveness, joined by two additional FCB agencies, with FCB Chicago ranking #4 and FCB Toronto ranking #7,
Ordinary and Extraordinary General Meeting of April 12, 202324.3.2023 21:30:00 CET | Press release
Montrouge, France, March 24, 2023 Ordinary and Extraordinary General Meeting of April 12, 2023 Procedures for Obtaining Information and Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, will hold its Ordinary and Extraordinary General Meeting (the “General Meeting”) on April 12, 2023, at 10:00 a.m. CET at the Company’s headquarters located at 177-181 Avenue Pierre Brossolette – 92120 Montrouge, France. The preliminary notice (avis de réunion) containing the detailed agenda, draft resolutions as well as instructions to participate and vote for this General Meeting was published in the French “Bulletin des AnnoncesLégalesObligatoires (BALO)” dated March 8, 2023 (No. 2300429). The meeting notice (avis de convocation) was published in the French “Bulletin des AnnoncesLégalesObligatoires (BALO)” dated March 24, 2023 (No. 2300600) and in the legal newspaper Affiches pari
TGS: Approval of 2022 Financial Result24.3.2023 20:03:58 CET | Press release
Oslo, Norway (24 March 2023) – The Board of Directors of TGS ASA has today approved the financial statements for 2022. The financial statements were prepared in accordance with IFRS. Please see the attachment for a summary of changes from the preliminary annual accounts announced on 9 February 2023. About TGS TGS provides scientific data and intelligence to companies active in the energy sector. In addition to a global, extensive and diverse energy data library, TGS offers specialized services such as advanced processing and analytics alongside cloud-based data applications and solutions. For more information, visit TGS.com (http://www.tgs.com) or contact: Sven Børre Larsen CFO Tel: +47 90 94 36 73 E-mail: firstname.lastname@example.org Attachment TGS Annual Accounts 2022 update
Nokia Corporation: Repurchase of own shares on 24.03.202324.3.2023 20:00:00 CET | Press release
Nokia Corporation Stock Exchange Release 24 March 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 24.03.2023 Espoo, Finland – On 24 March 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL306,0764.31CEUX7,3924.31AQEU2,6084.31TQEX6,3244.32Total322,4004.31 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and